Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

LGC and TranScrip Partners agree strategic alliance to enhance anti-infective and respiratory offerings

10 Sep 2013
Tags:  Biological
UK, 9 September 2013 - LGC, an international leader in the laboratory services, measurement standards, reference materials, genomics and proficiency testing marketplaces, and TranScrip Partners, a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management, have today announced a strategic alliance which will allow both parties to combine and enhance their offerings to clients, particularly in the areas of anti-infectives and respiratory disease.

TranScrip Partners supply a wide range of services including drug development and operations, regulatory affairs, microbiology, medical writing, translational medicine, drug safety and pharmacovigilance. LGC is a provider of high-integrity analytical laboratory services to support drug discovery, development and manufacture. With last year’s acquisition of Quotient Bio Analytical Sciences, LGC also has a leading bioanalytical facility with expertise spanning small molecules, biopharmaceuticals, biomarkers, microbiology and molecular services.

Dr David Griffiths, Director, Pharmaceutical Services at LGC, said, “We’re really excited by this development. LGC’s high quality laboratory services and TranScrip’s expertise in drug development strategy, medical writing and regulatory affairs complement each other beautifully. Whilst both companies support all therapeutic areas, we have a combined strength in anti-infectives and we are looking forward to discussing this alliance with our clients at the forthcoming ICAAC conference.”

Felicity Gabbay, Managing Partner at TranScrip Partners, added, “TranScrip have an enviable reputation for drug development, registration and post licensing support in anti-infectives, particularly antibiotics, and our alliance with LGC will allow us to extend this capability into vital laboratory support for these programmes. We are therefore delighted about the two companies coming together.”
On 3 October LGC is hosting an Autumn Seminar on Respiratory Product Development at their site in Fordham, Cambridgeshire, UK. Among the speakers will be TranScrip Partners’ Professor Tim Higenbottam, presenting on ‘Regulatory strategies for respiratory product development: opportunities and pitfalls’. To see the full programme and to register, please visit: Respiratory product development seminar.